Background: The purpose of the study was to determine whether breast cancers (BCs) that develop in women previously irradiated for Hodgkin lymphoma (HL) are biologically similar to sporadic BC.
introduction
Many long-term studies have demonstrated that girls and young women treated with chest radiotherapy (RT) for Hodgkin lymphoma (HL) have a significantly greater risk of developing breast cancer (BC), compared with the general population [1] [2] [3] . Known risk variables include radiation dose, extent of the radiation treatment field, the use of chemotherapy, and the age at RT exposure [3] [4] [5] [6] [7] [8] . There are limited published data, however, regarding the BC subtypes that develop in these high-risk patients, as hormone receptor (HR) status [estrogen receptor (ER) and progesterone receptor (PR)] or human epidermal growth factor receptor 2 (HER2) status was unavailable or unknown in 27%-64% of the previously reported populations [2, 9] .
BC is a heterogeneous disease, with six molecular subtypes identified based on differences in gene expression [10] [11] [12] [13] . While the subtypes are most appropriately defined by gene expression profiling, immunohistochemistry is often used as a surrogate to characterize four subtypes based on HR and HER2 status: luminal A (HR+/HER2−), luminal B (HR+/HER2+), Her2-overexpressing (HR−/HER2+), and basal-like (HR−/ HER2−) subtypes [14, 15] . Recognizing the BC subtypes that develop in previously irradiated breast tissue may help elucidate mechanisms of carcinogenesis in these patients as well as strategies for prevention and early detection.
In the current study, we review the pathologic features of BCs that developed in women previously treated with chest RT for HL to identify the histologic subtypes of these BCs and to determine whether radiation-associated BCs are biologically similar to sporadic BCs that developed in a nonirradiated, age-matched cohort.
methods
After approval from the Institutional Review Board, records of patients previously treated with chest RT for HL who subsequently developed BC were reviewed. Patients were included if they received chest RT before 2000 and had pathologic information available for the BC, including HR and HER2 status for invasive carcinomas. Exclusion criteria included patients who developed BC before or within 5 years of HL treatment and patients with breast sarcomas. All patient charts were reviewed for clinical and treatment information, including age at RT treatment, use of chemotherapy, age at diagnosis of BC, and pathologic features of the BC.
Breast carcinomas were classified as ductal carcinoma in situ (DCIS) or invasive carcinoma. For invasive carcinomas, ER, PR, and HER2 status were recorded. Invasive carcinomas were further characterized using immunohistochemistry as surrogates for tumor subtype: HR+HER2− ('luminal A'); HR +HER2+ ('luminal B'); HR−HER2+ ('HER2-enriched'); and HR−HER2− ('basal-like' or 'triple negative').
Patients were age-matched within 1 year to four women with sporadic BC (i.e. BC that developed in women who did not have a prior history of RT). The sporadic BC cohort excluded patients with known breast cancer (BRCA) I or II mutations. Histologic subtypes were analyzed for each group to determine whether there were any biologic differences between BC in previously irradiated patients and sporadic BC.
Descriptive statistics were used to evaluate patient and treatment characteristics. Analyses were carried out using Fisher's exact test of proportions. All statistical analyses were carried out using SAS v9.3 (SAS, Cary, NC, USA).
results
Between 1966 and 1999, 147 women who were previously treated with chest RT for HL and had a subsequent BC diagnosis were identified. Of these, 65 women with 71 BCs had complete pathologic information available, including HR and HER2 status for the invasive carcinomas, and were included in the analysis.
characteristics of HL patients who developed BC
Patient and treatment characteristics for the HL patients who developed BC are listed in Table 1 . The median age at the time of HL treatment was 23 years. All patients received chest RT and 54% received chemotherapy for their initial diagnosis of HL. The median interval from HL treatment to a BC diagnosis was 20 years, and the median age at the time of BC diagnosis was 44 years.
Eighty percent of patients were diagnosed with early stage (stage 0-II) BC. Of the 71 cancers detected, 20 (28%) were diagnosed as DCIS and 51 (72%) as invasive carcinoma. Six patients were diagnosed with bilateral BC. Thirty-eight (58%) patients underwent chemotherapy for BC, 26 (40%) underwent endocrine therapy, and 6 (9%) received trastuzumab. At a median follow-up of 10 years, 26 (40%) patients are alive and disease free, 7 (11%) are alive with BC, 6 (9%) died from BC, and 3 (5%) died from other causes. Twenty-three patients were lost to follow-up.
invasive breast cancer subtypes after HL
Of the 51 invasive cancers that developed in these patients previously irradiated for HL, 24 (47%) were HR+/HER2−, 2 (4%) were HR+/HER2+, 5 (10%) were HR−/HER2+, and 20 (39%) were HR−/HER2−. Of the 46 invasive cancers for which grade was available, 24 (48%) were high-grade carcinomas. One patient with a HR−/HER2− BC had a known BRCA1 mutation. Information regarding genetic testing was unavailable for the remaining patients.
As the relative risk of the development of BC following HL treatment is greatest when patients are exposed to RT under the age of 30, results were analyzed according to the patient's age at the time of RT treatment (≤29 years of age versus >30 years of age) to determine whether RT exposure to the breast at a young age impacts the types of BCs that develop (Table 2 ). There were no differences in the development of in situ versus invasive carcinomas according to age at the time of RT exposure. Of the 34 invasive cancers that developed in patients who were ≤29 years of age at the time of RT treatment, 16 (47%) were HR+/HER2− and Results were also analyzed according to whether patients received chemotherapy as part of their HL treatment to assess whether HL treatment-related menopause may have altered the biologic profile of the BCs (Table 3) . Of the 30 invasive cancers that developed in those patients who received chemotherapy for HL, 15 (50%) were HR+/HER2−, 1 (3%) HR+/HER2+, 2 (7%) HR−/HER2+, and 12 (40%) HR−/HER2−. This was similar to the invasive cancers that developed in patients who did not receive chemotherapy for HL (P = NS).
Most of the BCs (48%) developed >20 years after HL treatment (Table 4 ). There were no differences in the histologic subtypes of BCs that developed <10 years, between 11 and 20 years, and >20 years from HL treatment (P = NS).
invasive breast cancer subtypes after HL compared with age-matched cohort of sporadic BC Table 5 illustrates the characteristics of the 51 invasive BCs after HL treatment compared with 204 invasive cancers in an agematched cohort of patients with sporadic BC. In patients previously irradiated for HL, the invasive cancers were more likely to be HR−/HER2− and less likely to be HR+/HER2−, compared with invasive cancers that developed in the sporadic cohort (39% versus 14% and 47% versus 61%, respectively; P = 0.0003). There were also fewer HR+/HER2+ tumors, with 4% in the HL cohort compared with 14% in the sporadic cohort.
discussion
We found that invasive BCs arising in previously irradiated breast tissue were more likely to be triple-negative compared with agematched sporadic invasive BCs. They were less likely to be HR positive, particularly HR+/HER2+. There were no differences in the histologic subtype of BCs according to the age at which patients were exposed to RT, the use of chemotherapy for HL treatment, or the time from RT exposure to the development of BC.
Our findings are consistent with other published series [16] and suggest that radiation-associated BCs may have a more aggressive biologic profile than those arising in nonirradiated breast tissue. In a study comparing BCs in the general population with those in women treated with RT for HL before the age of 35, Dores et al. [16] found that women irradiated for HL had a >9-fold risk of developing ER-negative/PR-negative BC [standardized incidence ratio (SIR) = 9.31] compared with an approximately 5-fold risk of ER-positive/PR-positive tumors (SIR = 4.96). HER2 was not reported in this cohort. Interestingly, the SIR of ER-/PR-negative BCs increased over time, with 15-year survivors of HL having a nearly 2-fold higher relative risk of receptor-negative BC than receptor-positive disease (relative risk = 1.99, P = 0.002). Although the numbers are small in our series, we did not identify any statistically significant difference in the likelihood of developing HR-negative BC over time. We did, however, note a trend toward a greater number of HER2+ tumors with increasing time since RT exposure. a Information on whether chemotherapy was used for HL treatment was unavailable for one patient. Castiglioni et al. [17] also reported that BCs arising after irradiation were less likely to be ER and PR positive compared with a control group of sporadic BCs (50% versus 73% for ER, P = 0.009; 31% versus 58% for PR, P = 0.002). Furthermore, the biologic characteristics of the BCs appeared to be related to the time the breast was exposed to irradiation, with those irradiated after breast maturation, defined as 4 or more years after menarche, more likely to have triple-negative BCs compared with those irradiated during breast development (52% versus 6%, P < 0.0001). The development of HER2-positive tumors was also thought to be related to the timing of the exposure, with a higher percentage of HER2-positive tumors noted in patients irradiated during breast maturation compared with those irradiated after breast maturation (35% versus 12%, P = 0.046). In our series, we did not find any differences in the histologic subtype according to the age at which patients were exposed to RT; however, we recognize that the small numbers limit the analysis. We also found a trend toward more triple-negative BCs in those exposed after breast maturation. Further studies will be important to determine which specific molecular changes occur after RT exposure and how they may vary with respect to breast development.
Gene expression profiling data also suggest that BCs following the treatment of HL may have more adverse biologic features [18] . Broeks et al. identified two distinct clusters that separated BCs associated with RT exposure from sporadic BCs. RTassociated BCs tended to correlate with the chromosomal instability gene profile. They also more often expressed the intrinsic basal subtype, with 27% of cancers in women exposed to RT having basal-like properties. While not all triple-negative cancers are of the basal-like subtype, and not all basal-like subtypes are triple negative, our findings demonstrate that 39% of patients exposed to RT had HR−/HER2− cancers and confirm that immunohistochemistry is useful in providing an estimate of the gene expression profile of RT-associated BCs.
Our study differs from other published series in that both HR and HER2 status were included to simulate the biologic subtypes. We also identified four age-matched sporadic BCs for every one BC after HL to ensure that the types of BCs that developed after RT exposure were not simply a reflection of the young age at which these patients develop BC, as triple-negative BCs are more commonly diagnosed in women <40 years of age compared with HR-positive BCs [19] .
Limitations of our study include the retrospective nature and the use of immunohistochemistry as a surrogate for BC subtype rather than gene expression profiling. Another limitation and potential confounder is the lack of testing for BRCA mutations in most of the patients with BC after HL, given that BRCA1 mutations are often associated with triple-negative BCs. However, thus far, there are no data to suggest a correlation between HL and BRCA mutations.
Our findings suggest that there may be differing molecular pathways of breast carcinogenesis in breast tissue exposed to RT when compared with sporadic BCs that develop in nonirradiated breast tissue. Current screening recommendations for patients exposed to chest RT include breast magnetic resonance imaging (MRI), in addition to mammography. Breast MRI will be particularly important for RT-associated triple-negative cancers that may not be readily detected by mammography. Our findings also challenge current BC chemoprevention strategies that incorporate selective ER modulators or aromatase inhibitors, as these agents are only effective in preventing ER-positive tumors. Additional work is needed to improve the detection and prevention strategies for BCs that develop in previously irradiated breast tissue, particularly the triple-negative cancers.
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